Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

DoubleTree Bethesdan

Sep 23, 2019 7:00 AM - Sep 24, 2019 5:00 PM

8120 Wisconsin Avenue, , Bethesda, MD 20814 , USA

Biosimilars Conference

Session 5: Biosimilars in Practice – Critical Market Opportunities Awaiting to be Seized

Session Chair(s)

Erika  Satterwhite

Erika Satterwhite

Head of Global Biosimilars Policy

Mylan, United States

The US biologic payer and reimbursement framework has presented challenges for a biologic multi-source market, with a number of barriers blocking meaningful utilization and update. This session focuses on identifying mechanisms to overcome market access barriers in the US and build a suitable environment to release the untapped potential of biosimilar medicines competition.

Learning Objective : At the conclusion of this session, participants should be able to:
  • Appraise the impact of market barriers on biosimilar use in the US in 2019
  • Illustrate, by case studies, the impact on clinical use of biosimilars of common contracting features
  • Identify concrete policy solutions which, when implemented, can deliver the most significant improvement in creating a functioning US biosimilars market


Juliana Marguerite Reed, MS

US Biosimilar Industry Perspective

Juliana Marguerite Reed, MS

The Biosimilars Forum, United States

Executive Director

Murray  Aitken, MBA

Global Perspective 2030 on Biosimilars

Murray Aitken, MBA

IQVIA Institute for Human Data Science, United States

Executive Director

Elizabeth  Jex, JD


Elizabeth Jex, JD

Federal Trade Commission, United States

Attorney Advisor, Office of Policy Planning

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.